The MetALD-ALD Prediction Index (MAPI) is a validated diagnostic tool that utilizes five routine biomarkers (sex, MCV, GGT, HDL, HbA1c) to distinguish metabolic from alcohol-associated steatotic liver disease, bypassing the unreliability of patient self-reporting. Achieving ~76% diagnostic accuracy across international cohorts, MAPI establishes cost-effective triage cutoffs: a score $\le$ 0.09 effectively rules out significant alcohol involvement (94% NPV), while a score $\ge$ 0.33 identifies high-risk patients requiring confirmatory PEth testing.
CardiologyGastroenterology < class="penci-entry-title entry-title grid-title penci_grid_title">Biomarker panel distinguishes alcohol vs. metabolic liver disease